A daily pill that may shield stroke patients from stomach bleeding while on blood thinners

NCT ID NCT07730840

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether zastaprazan, a stomach-acid-blocking drug, can prevent upper gastrointestinal bleeding in adults who have recently had a transient ischemic attack (TIA) or ischemic stroke and are taking antiplatelet or anticoagulant medications. Participants take either zastaprazan or a placebo daily alongside their prescribed blood thinner. Researchers monitor for signs of bleeding or other side effects over up to three years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
zastaprazan, a potassium-competitive acid blocker (P-CAB) taken as a daily pill
What this could lead to
If it works, zastaprazan could become a standard preventive treatment to protect stroke and TIA patients from dangerous stomach bleeding while on blood thinners.
What could go wrong
This is a phase 3 trial, but the drug is still experimental. It may not reduce bleeding risk more than placebo, and any new drug carries unknown side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ISCHEMIC STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Asan Medical Center

    Seoul, 05505, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.